The Executive Committee on Global Health and Human Security has compiled draft proposals to further promote pharmaceutical and medical device regulatory harmonization in Asia. While the proposals revolve around initiatives for two main pillars - building clinical trial networks and…
BUSINESS
Enfortumab Vedotin Gets FDA Priority Review for Urothelial Cancer: Astellas/Seattle Genetics
Astellas Pharma said on September 17 that the US FDA has accepted a Biologics License Application for the investigational antibody drug conjugate (ADC) enfortumab vedotin, which is being codeveloped with Seattle Genetics. The submission made in July is supported by…
To read the full story
Related Article
- Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
December 20, 2019
- Astellas/Seattle Genetics’ ADC Filed in US for Urothelial Cancer
July 18, 2019
- Astellas’s ADC Enfortumab Vedotin Logs 44% ORR in Advanced Urothelial Cancer in PII
June 5, 2019
- Astellas/Seattle Genetics’ ADC Succeeds in PII Urothelial Cancer Study; US Filing Set for 2nd Half of 2019
March 29, 2019
BUSINESS
- Amgen Migraine Med Erenumab Hits Primary Goal in Japan PIII
May 29, 2020
- Bavencio Filed in Japan for Urothelial Carcinoma: Merck Biopharma/Pfizer
May 29, 2020
- Teijin Pharma Files Osteoporosis Drug Abaloparatide in Japan
May 29, 2020
- tella, Cenegenics Begin Clinical Trial of Stem Cell Therapy for COVID-19 in Mexico, Japan Study Planned in Autumn
May 29, 2020
- Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
May 29, 2020
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…